Metolazone
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Metolazone: From Edema and Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Metolazone is a thiazide-like diuretic, originally used for volume overload (edema) and hypertension. The TxGNN model predicts it may be effective for malignant renovascular hypertension, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Edema and hypertension (diuretic/antihypertensive use; the US license records provided contain no indication text) |
| Predicted New Indication | Malignant renovascular hypertension |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (all listed entries are ANDA generics) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available in the record. Based on known pharmacology, metolazone inhibits the Na⁺/Cl⁻ cotransporter in the distal convoluted tubule. This reduces circulating volume and lowers blood pressure. It is also used with loop diuretics in volume-overloaded states, including reduced GFR.
The link to the new indication is weak. Malignant renovascular hypertension is driven by the renin-angiotensin system. Volume depletion from a diuretic could stimulate renin release further. Diuretics are also not a standard therapy for hypertensive emergencies. The prediction is plausible only as an extension of the drug’s general antihypertensive use.
The other top TxGNN predictions are also unsupported:
- Malignant hypertensive renal disease (99.84%): the link is indirect, and aggressive volume depletion could worsen renal perfusion.
- Pulmonary hypertension (two entries, 99.83%): at most, diuretics offer symptomatic relief of right-heart volume overload. The 20 retrieved publications concern hypoxia biology in general (brain aging, cancer, multiple sclerosis, altitude) and never mention metolazone. They reflect keyword matching, not relevant evidence.
- Braddock syndrome (99.78%): no mechanistic rationale can be identified. This looks like a knowledge-graph artifact.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA076466 | Metolazone | Tablet (oral) | Sandoz Inc; Bryant Ranch Prepack |
| ANDA217563 | Metolazone | Tablet (oral) | Micro Labs Limited |
| ANDA213827 | Metolazone | Tablet (oral) | American Health Packaging |
Approved indication text is not included in the license records provided.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone, with no trials or relevant literature. The stated mechanism (volume depletion in a renin-driven condition) argues against benefit rather than for it. The pulmonary hypertension literature count is a keyword artifact.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- A targeted search for metolazone in renovascular or malignant hypertension, or a supporting mechanistic study
- Route compatibility and similarity-to-original assessments, both still pending
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.